SGLT-2 inhibitors demonstrate significant benefits in several areas: slowing the decline in eGFR, delaying kidney failure, reducing the incidence of ESRD, lowering cardiovascular mortality and heart failure hospitalizations, and improving cardiovascular health (84). Here, SLC5A2 is linked to heart failure.